Apimeds Pharmaceuticals Taps IBN to Boost Visibility for Its Digital Asset Infrastructure Subsidiary

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), a clinical-stage biopharmaceutical company focused on non-opioid pain therapies, has engaged IBN to assist with its corporate communications strategy. The move is designed to generate greater awareness for Apimeds and its wholly owned subsidiary, MindWave Innovations, which is developing institutional digital asset infrastructure that connects treasury, insurance, tokenized assets, and blockchain ecosystems.

MindWave’s platform combines insured custody, transparent reporting, and technology-driven portfolio management to support risk-aware yield on Bitcoin reserves and institutional participation in the digital asset economy. Through its MindChain ecosystem, MindWave operates four distinct verticals: InsurTech through BlockAssure, which is developing a Bermuda-framework platform applying Bitcoin reserves as regulatory capital to support life and property and casualty underwriting; ClimateTech through AQUAE and the ALCI index, measuring, verifying, and tokenizing ecosystem services into institutional-grade assets; HealthTech through the Apitox development program; and RWA Tech through Nexus Global Partners, bringing institutional real estate on-chain within a compliance-first, insurance-enhanced framework.

The engagement with IBN is expected to amplify Apimeds’ visibility across the investment community. IBN will leverage its investor-focused distribution network, including more than 5,000 syndication outlets, newsletters, social media channels, InvestorWire, and other outreach tools. As part of the Dynamic Brand Portfolio @ IBN, the network provides access to a vast array of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution to millions of followers, and a full suite of tailored corporate communications solutions.

For Texas, the announcement underscores the state’s growing role as a hub for both biotechnology and digital asset innovation. Apimeds, a biopharmaceutical firm, is expanding its reach into institutional digital assets through MindWave, reflecting a broader trend of convergence between traditional industries and blockchain technology. This could spur further investment and talent attraction in Texas, particularly in Austin, where MissionIR, the communications platform facilitating this engagement, is based.

Investors and industry observers should note that the latest news and updates relating to APUS are available in the company’s newsroom at https://ibn.fm/APUS. The full press release can be viewed at https://ibn.fm/PdvmC. For more information about Apimeds Pharmaceuticals US, Inc., visit www.ApimedsUS.com. Details about MissionIR and its services are available at MissionIR.